P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)

• ClinicalTrials.gov Identifier: NCT04960579
• Recruitment Status: Recruiting
• First Posted: July 14, 2021
• Last Update Posted: February 29, 2024
• Sponsor: Poseida Therapeutics, Inc.
• Collaborator: Roche-Genentech
• Information provided by (Responsible Party): Poseida Therapeutics, Inc.

Study Description

Brief Summary:

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

Condition or disease	Intervention/treatment	Phase
Multiple Myeloma	Biological: P-BCMA-ALLO1 CAR-T cells; Drug: Rimiducid	Phase 1

Detailed Description:

Phase 1/1b study: Phase 1 Part 1 is a weight-based dose escalation following a 3+3 design of dose-escalating cohorts. Phase 1 Part 2 includes administration at fixed doses. After enrollment, subjects may receive a lymphodepletion therapy regimen before administration of allogeneic CAR-T cells, administered as a single or multiple doses. Treated subjects will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated. Phase 1b of the study will undergo further expansion of cohorts/arms from Phase 1 Parts 1 or 2 to guide selection of Recommended Phase 2 Dose (RP2D).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 231 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)
• Actual Study Start Date: May 5, 2022
• Estimated Primary Completion Date: December 2027
• Estimated Study Completion Date: December 2039

Arms and Interventions

Arm	Intervention/treatment
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm S); Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm F); Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen F. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm N); Single weight-based IV administration of P-BCMA-ALLO1. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm P1); Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P1. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm P2); Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P2. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm R); Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen R. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm RS); Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RS. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm C); Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen C. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm160); Single fixed dose IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S, P1, P1.5 or P2. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm480); Single fixed dose IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S, P1, P1.5 or P2. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm P1.5); Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P1.5. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm RP1); Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP1. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm RP1.5); Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP1.5. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm RP2); Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP2. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm CP1); Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP1. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm CP1.5); Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP1.5. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator
Experimental: P-BCMA-ALLO1 CAR-T cells (Arm CP2); Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP2. Rimiducid may be administered as indicated.	Biological: P-BCMA-ALLO1 CAR-T cells; Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy; Drug: Rimiducid; Safety switch activator

Outcome Measures

Primary Outcome Measures :

1. Phase 1 Part 1: Assess the safety and maximum tolerated dose (MTD) of P-BCMA-ALLO1 based on dose limiting toxicities (DLT) [ Time Frame: Baseline through Day 28 ]
   Rate of dose limiting toxicities (DLT)
2. Phase 1 Part 2: Assess the safety and tolerability of P-BCMA-ALLO1 when administered as a fixed dose of cells. [ Time Frame: Baseline through 36 months ]
   Frequency and severity of adverse events, including cytokine release syndrome.
3. Phase 1b: The effect of cell dose and study arm to guide selection of Recommended Phase 2 Dose (RP2D). [ Time Frame: Baseline through 36 months ]
   Incidence and severity of cytokine release syndrome (CRS) events graded using American Society for Transplantation and Cellular Therapy (ASTCT) criteria (Lee, 2019).

Secondary Outcome Measures :

1. The safety of P-BCMA-ALLO1 [ Time Frame: Baseline through 15 years ]
   Incidence and severity of treatment-emergent adverse events
2. The anti-myeloma effect of P-BCMA-ALLO1 (ORR) in Phase 1 Parts 1 and 2 [ Time Frame: Baseline through 15 years ]
   According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Response Rate (ORR) - Percentage of patients with complete response (CR), very good partial response (VGPR), or partial response (PR)
3. The anti-myeloma effect of P-BCMA-ALLO1 (TTR) [ Time Frame: Baseline through 15 years ]
   According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Time to Response (TTR) - Time to complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease
4. The anti-Myeloma effect of P-BCMA-ALLO1 (DOR) [ Time Frame: Baseline through 15 years ]
   According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Duration of Response - Time from complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease
5. The anti-Myeloma effect of P-BCMA-ALLO1 (PFS) [ Time Frame: Baseline through 15 years ]
   According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Progression Free Survival (PFS) - Time from P-BCMA-ALLO1 treatment to progressive disease
6. The anti-Myeloma effect of P-BCMA-ALLO1 (OS) [ Time Frame: Baseline through 15 years ]
   According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Survival (OS) - Duration of survival from time of treatment with P-BCMA-ALLO1

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Must have signed written, informed consent.
2. Males or females, ≥18 years of age.
3. Must have a confirmed diagnosis of active MM.
4. Must have measurable MM.
5. Must have relapsed / refractory MM, having received treatment with a proteasome inhibitor, immunomodulatory agent (IMiD), and anti-CD38 therapy.
6. Must be willing to practice birth control from the time of Screening and throughout the first year of the study after P-BCMA-ALLO1 administration.
7. Must have a negative serum pregnancy test at Screening and a negative urine pregnancy test within 3 days prior to initiating the lymphodepletion therapy regimen (females of childbearing potential).
8. Must be at least 90 days since autologous stem cell transplant, if performed.
9. Must have adequate vital organ function within pre-determined parameters.
10. Must have recovered from toxicities due to prior therapies.
11. Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

Exclusion Criteria:

1. Is pregnant or lactating.
2. Has inadequate venous access.
3. Has active hemolytic anemia, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, disseminated intravascular coagulation, leukostasis, or amyloidosis.
4. Has an active second malignancy (not disease-free for at least 5 years) in addition to MM, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma.
5. Has active autoimmune disease.
6. Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy, etc.
7. Has an active systemic infection.
8. Has a history of hepatitis B, hepatitis C virus, human immunodeficiency virus (HIV), or human T-lymphotropic virus (HTLV) infection, or any immunodeficiency syndrome. Subjects with a history of treated hepatitis C can be enrolled if negative by Hepatitis C PCR on multiple occasions and with medical monitor approval.
9. Is positive for cytomegalovirus (CMV) by PCR, CMV immunoglobulin M (IgM) antibody, or Coronavirus disease 2019 (COVID-19) by PCR.
10. Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia.
11. Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol.
12. Has received prior allogeneic cellular therapy or gene therapy.
13. Has received anti-cancer medications within 2 weeks of the time of initiating conditioning LD therapy.
14. Has received monoclonal antibody therapy within 4 weeks of initiating conditioning LD therapy.
15. Has received immunosuppressive medications within 2 weeks of the time of administration of P-BCMA-ALLO1, and/or expected to require them while on study.
16. Has received systemic corticosteroid therapy within 1 week or 5 half-lives (whichever is shorter) of the administration of P-BCMA-ALLO1 or is expected to require it during the course of the study.
17. Has CNS metastases or symptomatic CNS involvement of their myeloma.
18. Has a history of severe immediate hypersensitivity reaction to any of the agents used in this study.
19. Has a history of having undergone allogeneic stem cell transplantation, or any other allogeneic or xenogeneic transplant, or has undergone autologous transplantation within 90 days.
20. Arms R, RS, RP1, RP1.5 and RP2 Only: a) Has received a live vaccine within the last 28 days of the first administration of agents used in Arm R or RS, b) Has any known hypersensitivity or severe reactions or toxicity to agents used in Arms R or RS.

Contacts and Locations

Contacts

Contact: Angie Schinkel; 858-779-3103; clinicaltrials@poseida.com

Locations

United States, California

University of California San Diego; Recruiting

San Diego, California, United States, 92093

University of California San Francisco; Terminated

San Francisco, California, United States, 94143

United States, Illinois

Advocate Aurora Health; Terminated

Park Ridge, Illinois, United States, 66068

United States, Iowa

University of Iowa; Recruiting

Iowa City, Iowa, United States, 52242

United States, Kansas

University of Kansas Medical Center; Recruiting

Kansas City, Kansas, United States, 66160

United States, Maryland

University of Maryland Greenebaum Comprehensive Cancer Center; Recruiting

Baltimore, Maryland, United States, 21201

United States, Michigan

Wayne State - Karmanos Cancer Institute; Recruiting

Detroit, Michigan, United States, 48201

United States, New York

Roswell Park Comprehensive Cancer Center; Recruiting

Buffalo, New York, United States, 14263

United States, Ohio

University of Cincinnati; Recruiting

Cincinnati, Ohio, United States, 45221

United States, Oklahoma

University of Oklahoma, Health Sciences Center; Active, not recruiting

Oklahoma City, Oklahoma, United States, 73104

United States, Tennessee

Vanderbilt University Medical Center; Recruiting

Nashville, Tennessee, United States, 37232

United States, Texas

Sarah Cannon Research Institute - St. David's South Austin Medical Center; Recruiting

Austin, Texas, United States, 78704

Houston Methodist Research Institute; Recruiting

Houston, Texas, United States, 77030

Sarah Cannon Research Institute - Methodist Healthcare; Recruiting

San Antonio, Texas, United States, 78229

Sponsors and Collaborators

Poseida Therapeutics, Inc.

Roche-Genentech

Investigators

• Study Director: Rajesh Belani, M.D.; Vice President, Clinical Development

More Information

• Responsible Party: Poseida Therapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT04960579
• Other Study ID Numbers: P-BCMA-ALLO1-001
• First Posted: July 14, 2021
• Last Update Posted: February 29, 2024
• Last Verified: February 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Multiple Myeloma; Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases